Ranexa
The anti-anginal and anti-ischemic properties of ranolazine are not dependent on reductions in heart rate or blood pressure. Ranolazine was approved on January 27, 2006, for the treatment of chronic angina. Because ranolazine prolongs the QT interval, it should be reserved for patients who have not achieved an adequate response with other anti-anginal drugs.
RanolazineCV TherapeuticsAnti-anginal agent approved for patients not responsive to other therapies
The anti-anginal and anti-ischemic properties of ranolazine are not dependent on reductions in heart rate or blood pressure. Ranolazine was approved on January 27, 2006, for the treatment of chronic angina. Because ranolazine prolongs the QT interval, it should be reserved for patients who have not achieved an adequate response with other anti-anginal drugs.
Efficacy. The efficacy of ranolazine in the treatment of angina was evaluated in patients with chronic angina who remained symptomatic despite treatment with the maximum dose of an anti-anginal agent. In the ERICA (Efficacy of Ranolazine in Chronic Angina) trial, 565 patients were randomized to receive an initial dose of ranolazine 500 mg bid or placebo for 1 week, followed by 6 weeks of treatment with ranolazine 1,000 mg bid or placebo in addition to concomitant treatment with amlodipine 10 mg qd. The mean number of angina attacks per week was 3.3 in the ranolazine group compared with 4.3 in the placebo group (P=.028). Likewise, the mean number of nitroglycerin doses per week was 2.7 in the ranolazine group compared with 3.6 in the placebo group (P=.014). In the CARISA (Combination Assessment of Ranolazine In Stable Angina) study, 823 chronic angina patients were randomized to receive 12 weeks of treatment with twice-daily ranolazine 750 mg, 1,000 mg, or placebo while continuing daily doses of atenolol 50 mg, amlodipine 5 mg, or diltiazem 180 mg. Statistically significant (P<.05) increases in modified Bruce treadmill exercise duration and time to angina were observed for each ranolazine dose versus placebo, at both trough (12 h after dosing) and peak (4 h after dosing) plasma levels. For the treadmill test, the mean difference from placebo in exercise duration at peak plasma levels was 34 seconds for the 750-mg ranolazine dose compared with 26 seconds for the 1,000-mg dose (P≤.05). Likewise, the mean difference from placebo in time to angina at peak plasma concentration was 38 seconds for both doses (P≤.005). The mean number of angina attacks per week in this study was 2.5 and 2.1 for the 750- and 1,000-mg ranolazine groups, respectively, compared with 3.3 for placebo (P=.006 and <.001, respectively). The mean number of nitroglycerin doses per week was 2.1 and 1.8 for the 750- and 1,000-mg ranolazine groups, respectively, compared with 3.1 for placebo (P=.016 and <.001, respectively).
Dosing. Ranolazine should be initiated at 500 mg bid and increased to 1,000 mg bid as needed, based on clinical symptoms. The maximum recommended daily dose of ranolazine is 1,000 mg bid. Baseline and follow-up ECGs should be obtained to evaluate effects on the QT interval. The concomitant administration of ranolazine and other commonly administered cardiovascular medications (amlodipine, beta blockers, nitrates, antihypertensive agents) is well tolerated. Ranolazine may be taken with or without meals.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
